Afternoon trading October 24, page-96

@valvesound

Check out RHY - their bowel cancer test was developed by the CSIRO; is far more advanced than BD1's, has bigger scale & potential given BD1's is actually a niche test only for women who are BRCA1/2 genetic positive, thus only 5-10% of women with breast cancer.

Today's volume IMO cleared the decks for a larger, higher volume move in the days to come as the last remnants of the IPO holders were flushed.

With $7.7m cash (& 100m SOI) its compelling & the 4C; development milestones & (i hope) a fresh investor presso will be amazing catalysts for the stock going forward.